# A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

> **NCT06390722** · PHASE3 · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Atopic Dermatitis
- Sleep Disturbance

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Placebo for Upadacitinib

## Key facts

- **NCT ID:** NCT06390722
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-23
- **Primary completion:** 2026-01-05
- **Final completion:** 2026-07-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** strategic decision
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06390722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06390722, "A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06390722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*